Research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a research note issued on Sunday. The firm set a "sell" rating on the stock.
InspireMD Price Performance
NSPR stock traded up $0.14 during midday trading on Friday, reaching $2.59. The company had a trading volume of 14,282 shares, compared to its average volume of 34,991. The firm has a 50-day moving average price of $2.77 and a 200-day moving average price of $2.74. The company has a market capitalization of $79.34 million, a P/E ratio of -3.45 and a beta of 0.74. InspireMD has a 1 year low of $1.87 and a 1 year high of $3.80.
Institutional Investors Weigh In On InspireMD
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parkman Healthcare Partners LLC raised its holdings in shares of InspireMD by 721.2% during the fourth quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company's stock valued at $2,248,000 after acquiring an additional 750,635 shares in the last quarter. Affiance Financial LLC grew its stake in shares of InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock worth $497,000 after acquiring an additional 5,376 shares during the last quarter. Huntleigh Advisors Inc. bought a new position in shares of InspireMD during the first quarter valued at $316,000. Essex Investment Management Co. LLC bought a new position in InspireMD in the 4th quarter worth about $191,000. Finally, Northern Trust Corp grew its position in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after purchasing an additional 24,452 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors.
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
See Also
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
